Clinical Trials
15 trialsNCT07359456 2026-05-19
COLIBRI-GI
UNICANCER
Phase 2 Not yet recruiting
NCT00959647 2026-05-08
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Genentech, Inc.
Phase 2 Completed
NCT07446322 2026-05-05
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
Oncolytics Biotech
Phase 2 Recruiting
NCT05004350 2026-04-30
NAUTICALCRC
Pierre Fabre Medicament
Phase 2 Completed
NCT07381309 2026-04-28
VVSHIP
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07323576 2026-02-09
INAVO-CRC
Hoffmann-La Roche
Phase 2 Withdrawn
NCT05605509 2026-02-06
RP-6306 in Patients With Advanced Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT04587128 2026-02-05
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT06106308 2026-01-12
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Cardiff Oncology
Phase 2 Active not recruiting
NCT06747845 2025-09-16
ParpVax2
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT02820857 2025-09-03
BEVANEC
Hospices Civils de Lyon
Phase 2 Completed
NCT05480306 2025-08-03
DeFianCe
Leap Therapeutics, Inc.
Phase 2 Completed
NCT03806309 2025-07-25
TEDOPAM
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Active not recruiting
NCT03186326 2025-06-29
SAMCO
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT07021950 2025-06-15
AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting